ENGN
enGene Holdings Inc

1,224
Mkt Cap
$436.55M
Volume
538,886.00
52W High
$11.14
52W Low
$2.65
PE Ratio
-3.48
ENGN Fundamentals
Price
$6.60
Prev Close
$6.76
Open
$6.85
50D MA
$7.44
Beta
0.26
Avg. Volume
349,781.39
EPS (Annual)
-$1.46
P/B
1.68
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
Leerink Partnrs Reduces Earnings Estimates for enGene
enGene Holdings Inc. (NASDAQ:ENGN - Free Report) - Leerink Partnrs decreased their FY2030 earnings estimates for shares of enGene in a research report issued to clients and investors on Thursday...
MarketBeat·3d ago
News Placeholder
More News
News Placeholder
Leerink Partnrs Brokers Reduce Earnings Estimates for enGene
enGene Holdings Inc. (NASDAQ:ENGN - Free Report) - Investment analysts at Leerink Partnrs decreased their FY2026 earnings per share estimates for shares of enGene in a report released on Tuesday...
MarketBeat·5d ago
News Placeholder
Leerink Partnrs Estimates enGene FY2030 Earnings
enGene Holdings Inc. (NASDAQ:ENGN - Free Report) - Research analysts at Leerink Partnrs issued their FY2030 earnings estimates for shares of enGene in a research report issued on Tuesday, November...
MarketBeat·6d ago
News Placeholder
enGene (NASDAQ:ENGN) Price Target Raised to $19.00 at Morgan Stanley
Morgan Stanley lifted their price target on shares of enGene from $18.00 to $19.00 and gave the stock an "overweight" rating in a research note on Wednesday...
MarketBeat·7d ago
News Placeholder
enGene (NASDAQ:ENGN) Given New $21.00 Price Target at Citizens Jmp
Citizens Jmp boosted their target price on shares of enGene from $18.00 to $21.00 and gave the stock a "market outperform" rating in a report on Wednesday...
MarketBeat·8d ago
News Placeholder
enGene Announces Pricing of $130 Million Public Offering of Common Shares and Pre-Funded Warrants
enGene Holdings Inc. (Nasdaq: ENGN, enGene or the Company), a clinical-stage, non-viral genetic medicines company, today announced the pricing of its previously announced underwritten public offering...
Business Wire·8d ago
News Placeholder
enGene Announces Proposed Public Offering of Common Shares
enGene Holdings Inc. (Nasdaq: ENGN, enGene or the Company), a clinical-stage, non-viral genetic medicines company, today announced that it has commenced an underwritten public offering of its common...
Business Wire·8d ago
News Placeholder
enGene (NASDAQ:ENGN) Upgraded at Raymond James Financial
Raymond James Financial raised shares of enGene from an "outperform" rating to a "strong-buy" rating and set a $27.00 price objective for the company in a report on Tuesday...
MarketBeat·9d ago
News Placeholder
ENGN Stock Soars On Hopeful Data From Bladder Cancer Study
The company is now looking forward to submitting an application for approval of the cancer therapy to the U.S. Food and Drug Administration in the second half of 2026.
Stocktwits·10d ago
News Placeholder
Detalimogene Demonstrates Improved Complete Response Rate of 62% at 6 Months
enGene Holdings Inc. (Nasdaq: ENGN or enGene or the Company), a clinical-stage, non-viral genetic medicines company, today reported additional preliminary data from the pivotal cohort of its ongoing...
Business Wire·10d ago

Latest ENGN News

View

Advertisement|Remove ads.

Advertisement|Remove ads.